QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-leap-therapeutics-stock-on-thursday

Leap Therapeutics shares are plunging after rebranding as Cypherpunk, pivoting to a Zcash treasury and announcing a $200M stock...

 leap-therapeutics-q3-eps-008-beats-024-estimate

Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0...

 leap-therapeutics-reports-final-results-from-part-b-of-defiance-study-phase-2-study-of-sirexatamab-in-mss-crc-patients-who-have-received-one-prior-systemic-therapy-for-advanced-disease

Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high populationIncreasing DKK1 levels furt...

 why-is-leap-therapeutics-down-9-in-pre-market-trading

Leap Therapeutics is trading lower in pre-market following a $58.9 million private placement led by Winklevoss Capital.

 leap-therapeutics-secures-589m-pipe-led-by-winklevoss-capital-for-9585m-shares-and-warrants-to-buy-719m-shares

Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION